Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.

dc.contributor.author

Gnanakaran, S

dc.contributor.author

Daniels, MG

dc.contributor.author

Bhattacharya, T

dc.contributor.author

Lapedes, AS

dc.contributor.author

Sethi, A

dc.contributor.author

Li, M

dc.contributor.author

Tang, H

dc.contributor.author

Greene, K

dc.contributor.author

Gao, H

dc.contributor.author

Haynes, BF

dc.contributor.author

Cohen, MS

dc.contributor.author

Shaw, GM

dc.contributor.author

Seaman, MS

dc.contributor.author

Kumar, A

dc.contributor.author

Gao, F

dc.contributor.author

Montefiori, DC

dc.contributor.author

Korber, B

dc.contributor.editor

Fraser, Christophe

dc.coverage.spatial

United States

dc.date.accessioned

2011-06-21T17:31:13Z

dc.date.issued

2010-10-07

dc.description.abstract

A steady increase in knowledge of the molecular and antigenic structure of the gp120 and gp41 HIV-1 envelope glycoproteins (Env) is yielding important new insights for vaccine design, but it has been difficult to translate this information to an immunogen that elicits broadly neutralizing antibodies. To help bridge this gap, we used phylogenetically corrected statistical methods to identify amino acid signature patterns in Envs derived from people who have made potently neutralizing antibodies, with the hypothesis that these Envs may share common features that would be useful for incorporation in a vaccine immunogen. Before attempting this, essentially as a control, we explored the utility of our computational methods for defining signatures of complex neutralization phenotypes by analyzing Env sequences from 251 clonal viruses that were differentially sensitive to neutralization by the well-characterized gp120-specific monoclonal antibody, b12. We identified ten b12-neutralization signatures, including seven either in the b12-binding surface of gp120 or in the V2 region of gp120 that have been previously shown to impact b12 sensitivity. A simple algorithm based on the b12 signature pattern was predictive of b12 sensitivity/resistance in an additional blinded panel of 57 viruses. Upon obtaining these reassuring outcomes, we went on to apply these same computational methods to define signature patterns in Env from HIV-1 infected individuals who had potent, broadly neutralizing responses. We analyzed a checkerboard-style neutralization dataset with sera from 69 HIV-1-infected individuals tested against a panel of 25 different Envs. Distinct clusters of sera with high and low neutralization potencies were identified. Six signature positions in Env sequences obtained from the 69 samples were found to be strongly associated with either the high or low potency responses. Five sites were in the CD4-induced coreceptor binding site of gp120, suggesting an important role for this region in the elicitation of broadly neutralizing antibody responses against HIV-1.

dc.description.version

Version of Record

dc.identifier

http://www.ncbi.nlm.nih.gov/pubmed/20949103

dc.identifier.eissn

1553-7358

dc.identifier.uri

https://hdl.handle.net/10161/4454

dc.language

eng

dc.language.iso

en_US

dc.publisher

Public Library of Science (PLoS)

dc.relation.ispartof

PLoS Comput Biol

dc.relation.isversionof

10.1371/journal.pcbi.1000955

dc.relation.journal

Plos Computational Biology

dc.subject

Algorithms

dc.subject

Amino Acid Sequence

dc.subject

Antibodies, Neutralizing

dc.subject

Artificial Intelligence

dc.subject

Cluster Analysis

dc.subject

Computational Biology

dc.subject

DNA Mutational Analysis

dc.subject

Epitope Mapping

dc.subject

Epitopes, T-Lymphocyte

dc.subject

HIV Envelope Protein gp120

dc.subject

HIV Envelope Protein gp41

dc.subject

HIV-1

dc.subject

Humans

dc.subject

Logistic Models

dc.subject

Models, Molecular

dc.subject

Mutation

dc.subject

Neutralization Tests

dc.subject

Phylogeny

dc.subject

Sequence Alignment

dc.title

Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.

dc.title.alternative
dc.type

Journal article

duke.contributor.orcid

Gao, F|0000-0001-8903-0203

duke.contributor.orcid

Montefiori, DC|0000-0003-0856-6319

duke.date.pubdate

2010-10-0

duke.description.issue

10

duke.description.volume

6

pubs.author-url

http://www.ncbi.nlm.nih.gov/pubmed/20949103

pubs.begin-page

e1000955

pubs.issue

10

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Duke

pubs.organisational-group

Duke Cancer Institute

pubs.organisational-group

Duke Human Vaccine Institute

pubs.organisational-group

Global Health Institute

pubs.organisational-group

Immunology

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Institutes and Provost's Academic Units

pubs.organisational-group

Medicine

pubs.organisational-group

Medicine, Duke Human Vaccine Institute

pubs.organisational-group

Medicine, Infectious Diseases

pubs.organisational-group

School of Medicine

pubs.organisational-group

Surgery

pubs.organisational-group

Surgery, Surgical Sciences Section for AIDS Research & Development

pubs.organisational-group

University Institutes and Centers

pubs.publication-status

Published online

pubs.volume

6

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
283651900020.pdf
Size:
6.42 MB
Format:
Adobe Portable Document Format